Passage Bio (NASDAQ:PASG) Trading Down 6.5% – What’s Next?

Posted by Francis Steltz on Jul 28th, 2026

Shares of Passage Bio, Inc. (NASDAQ:PASG – Get Free Report) traded down 6.5% on Monday . The stock traded as low as $4.55 and last traded at $4.62. 29,524 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 52,155 shares. The stock had previously closed at $4.94.

Wall Street Analysts Forecast Growth

PASG has been the subject of several research reports. Guggenheim lowered Passage Bio from a “buy” rating to a “neutral” rating in a report on Wednesday, June 10th. UBS Group downgraded Passage Bio to a “neutral” rating in a report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Passage Bio in a research report on Wednesday, June 24th. Wedbush reaffirmed a “neutral” rating and set a $8.00 price objective (down from $32.00) on shares of Passage Bio in a research report on Tuesday, April 21st. Finally, TD Cowen cut shares of Passage Bio from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $13.25.

Check Out Our Latest Stock Analysis on Passage Bio

Passage Bio Stock Down 6.5%

The stock has a market capitalization of $14.82 million, a price-to-earnings ratio of -0.39 and a beta of 1.42. The company’s 50-day simple moving average is $5.19 and its 200 day simple moving average is $7.71.

Passage Bio (NASDAQ:PASG – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($2.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.76) by $0.40. On average, equities analysts expect that Passage Bio, Inc. will post -8.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Passage Bio

In related news, major shareholder Lynx1 Capital Management Lp bought 50,055 shares of Passage Bio stock in a transaction that occurred on Thursday, June 25th. The stock was purchased at an average cost of $4.12 per share, for a total transaction of $206,226.60. Following the acquisition, the insider owned 673,759 shares in the company, valued at $2,775,887.08. This trade represents a 8.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Passage Bio

A number of large investors have recently added to or reduced their stakes in PASG. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Passage Bio in the fourth quarter valued at approximately $118,000. Quadrature Capital Ltd bought a new stake in shares of Passage Bio during the 4th quarter worth $148,000. Squarepoint Ops LLC bought a new stake in shares of Passage Bio during the 3rd quarter worth $188,000. Geode Capital Management LLC boosted its holdings in shares of Passage Bio by 15.1% during the 4th quarter. Geode Capital Management LLC now owns 31,397 shares of the company’s stock worth $371,000 after buying an additional 4,114 shares during the period. Finally, Yiheng Capital Management L.P. acquired a new position in Passage Bio in the 4th quarter valued at $405,000. Institutional investors own 53.48% of the company’s stock.

About Passage Bio

(Get Free Report)

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.